.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Johnson and Johnson
Queensland Health
Accenture
Fuji
Merck
Cantor Fitzgerald
Federal Trade Commission
Medtronic
Express Scripts

Generated: July 20, 2017

DrugPatentWatch Database Preview

VESICARE Drug Profile

« Back to Dashboard

Which patents cover Vesicare, and when can generic versions of Vesicare launch?

Vesicare is a drug marketed by Astellas and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-one patent family members in twenty-two countries.

The generic ingredient in VESICARE is solifenacin succinate. There are twenty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.

Summary for Tradename: VESICARE

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list53
Clinical Trials: see list47
Patent Applications: see list1,014
Drug Prices:see details
DailyMed Link:VESICARE at DailyMed

Pharmacology for Tradename: VESICARE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas
VESICARE
solifenacin succinate
TABLET;ORAL021518-001Nov 19, 2004ABRXYesNo6,017,927► SubscribeYY ► Subscribe
Astellas
VESICARE
solifenacin succinate
TABLET;ORAL021518-002Nov 19, 2004ABRXYesYes6,017,927► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: VESICARE

Drugname Dosage Strength RLD Submissiondate
solifenacin succinateTablets5 mg and 10 mgVesicare4/8/2009

Non-Orange Book Patents for Tradename: VESICARE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,174,896 Quinuclidine derivatives and medicinal composition thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VESICARE

Country Document Number Estimated Expiration
Spain2193208► Subscribe
Japan3014457► Subscribe
Austria233761► Subscribe
South Korea100386487► Subscribe
China1045601► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VESICARE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2004 00037Denmark► Subscribe
0801067/01Switzerland► SubscribePRODUCT NAME: SOLIFENACIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57203 12.05.2006
C0032France► SubscribePRODUCT NAME: SUCCINATE DE SOLIFENACINE; NAT. REGISTRATION NO/DATE: NL 30 109 20040816; FIRST REGISTRATION: NL - RVG 29 151 20031216
C014/2004Ireland► SubscribeSPC014/2004: 20050803, EXPIRES: 20181215
133Luxembourg► Subscribe91133, EXPIRES: 20181118
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Teva
Deloitte
Harvard Business School
US Department of Justice
Accenture
Argus Health
Dow
McKesson
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot